Phospho-SHC1 (S36) Antibody

What is SHC1 and why is the S36 phosphorylation site significant?

SHC1 (Src homology 2 domain-containing transforming protein 1) is a proto-oncogene encoding adaptor proteins that exist in three isoforms: p66Shc, p52Shc, and p46Shc. The p66Shc isoform contains a unique CH2 domain with a critical serine residue at position 36. Phosphorylation at S36 is particularly significant because it governs the pro-oxidant and pro-apoptotic functions of p66Shc by facilitating its mitochondrial translocation . This phosphorylation serves as a molecular switch in oxidative stress response pathways and has been implicated in various pathologies, including ischemia/reperfusion injury, aging, and cardiovascular diseases .

Which kinases are responsible for SHC1 S36 phosphorylation?

While PKCβ was initially proposed as the primary S36 kinase, recent evidence has established that cJun N-terminal kinases (JNKs) play a critical role in phosphorylating this residue. Research using specific inhibitors demonstrated a pronounced decrease in p66ShcS36 phosphorylation specifically when JNK1/2 was inhibited. Direct phosphorylation of recombinant p66Shc by JNK1, but not PKCβ, has been demonstrated in vitro . This JNK1/2-dependent regulation of p66ShcS36 phosphorylation has significant implications for reactive oxygen species (ROS) production and cell death pathways.

How does phosphorylation at S36 affect SHC1 function compared to other phosphorylation sites?

SHC1 contains multiple phosphorylation sites that serve distinct signaling functions:

While tyrosine phosphorylation sites (Y239/240, Y313) primarily mediate classical growth factor signaling through the Ras pathway, S36 phosphorylation serves a distinct function in stress response pathways, particularly in regulating mitochondrial ROS production and apoptosis .

What controls should be included when validating a phospho-SHC1 (S36) antibody?

Rigorous validation of phospho-specific antibodies requires multiple independent approaches:

• Western blotting with stimulated/unstimulated samples: Compare samples containing phosphorylated versus unphosphorylated protein. For SHC1, treatment with H₂O₂ or TNF-α can increase S36 phosphorylation .

• Phosphatase treatment controls: Treat half of your positive control lysate with lambda phosphatase to remove phosphorylation and confirm antibody specificity.

• Peptide competition assays: Pre-incubate antibody with phosphorylated and non-phosphorylated peptides to demonstrate phospho-specificity.

• Genetic controls: When available, use cells expressing phosphorylation-site mutants (S36A) or SHC1 knockout cells as negative controls.

• Signal correlations: Verify that signal intensity correlates with treatments known to modulate S36 phosphorylation (e.g., oxidative stress, hypoxia/reoxygenation) .

How do monoclonal and polyclonal phospho-SHC1 (S36) antibodies differ in research applications?

What are the optimal conditions for detecting phospho-SHC1 (S36) by Western blotting?

Optimized Western Blotting Protocol for Phospho-SHC1 (S36) Detection:

• Sample preparation:

  • Include phosphatase inhibitors (10 mM NaF, 1 mM Na₃VO₄, 1 mM PMSF, phosphatase inhibitor cocktail)

  • Lyse cells directly in hot Laemmli sample buffer for immediate phospho-protein denaturation

  • For better detection, use TNF-α stimulation (20 ng/mL for 5 minutes) as a positive control

• SDS-PAGE separation:

  • Use 10% gels for optimal resolution of p66Shc (66 kDa)

  • Load 20-40 μg total protein per lane

• Transfer conditions:

  • Transfer to PVDF membrane (preferred over nitrocellulose)

  • Use wet transfer at 100V for 1 hour or 30V overnight at 4°C

• Blocking and antibody incubation:

  • Block with 5% BSA (not milk) in TBST to prevent phosphatase activity

  • Incubate with primary antibody at 1:1000 dilution overnight at 4°C

  • Wash extensively (4 × 10 minutes) with TBST

  • Detect with appropriate HRP-conjugated secondary antibody

• Expected results:

  • Phospho-SHC1 (S36) appears primarily in the p66Shc isoform at ~66 kDa

  • May observe additional bands at 52 kDa and 46 kDa corresponding to other SHC1 isoforms

How should phospho-SHC1 (S36) antibodies be used for immunohistochemistry?

For optimal IHC detection of phospho-SHC1 (S36):

• Tissue preparation:

  • Use freshly fixed tissues (10% neutral buffered formalin, 24 hours)

  • Paraffin embedding should be performed promptly after fixation

  • Cut 4-5 μm thick sections

• Antigen retrieval:

  • Tris-EDTA buffer (pH 9.0) is recommended for phospho-epitopes

  • Heat-induced epitope retrieval (pressure cooker method) for 20 minutes

• Blocking and antibody incubation:

  • Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

  • Block nonspecific binding with 5% normal goat serum

  • Incubate with phospho-SHC1 (S36) antibody at 1:100-1:300 dilution at 4°C overnight

  • Use appropriate HRP-polymer detection system

• Controls:

  • Include phosphatase-treated sections as negative controls

  • For human tissue samples, tonsil tissue has been validated as a positive control

What are the most reliable experimental models for studying SHC1 S36 phosphorylation?

Several validated experimental models exist for studying SHC1 S36 phosphorylation:

• Cell culture models:

  • HeLa cells treated with TNF-α (20 ng/mL, 5 minutes) show robust S36 phosphorylation

  • Mouse embryonic fibroblasts (MEFs) exposed to H₂O₂ or hypoxia/reoxygenation

  • HL-1 cardiomyocytes as a model for cardiac stress responses

  • Human breast cancer cell lines with different EGFR/HER2 expression profiles (MDA-231, MDA-MB-468, BT474)

• Animal models:

  • Mouse models of ischemia/reperfusion injury

  • Preimplantation mouse embryos for developmental studies

• Genetic tools:

  • JNK1/2 knockout MEFs to study kinase regulation of S36 phosphorylation

  • S36E phosphomimetic mutants to study phosphorylation-dependent functions

  • Flag-GFP-tagged wild-type and mutant p66Shc constructs for overexpression studies

How can researchers differentiate true phospho-SHC1 (S36) signal from nonspecific binding?

To distinguish true phospho-SHC1 (S36) signal from artifacts:

• Include proper controls:

  • Unstimulated/stimulated sample pairs

  • Phosphatase-treated samples

  • Phospho-blocking peptide competition

  • S36A mutant expression (if available)

• Verify molecular weight:

  • The primary band should appear at ~66 kDa (p66Shc)

  • Other SHC1 isoforms (p52, p46) may show weaker or no signal at S36 phosphorylation

• Validate with multiple detection methods:

  • Confirm Western blot findings with immunoprecipitation followed by phospho-specific detection

  • Use phosphoproteomics approaches for independent validation

  • Apply multiple antibodies targeting different epitopes around the S36 site

• Correlate with functional outcomes:

  • S36 phosphorylation should correlate with increased ROS production

  • Mitochondrial translocation of p66Shc should increase with S36 phosphorylation

  • JNK inhibitors should diminish S36 phosphorylation signal

Why might phospho-SHC1 (S36) antibody signal be unexpectedly low even after stimulation?

Several factors can contribute to weak phospho-SHC1 (S36) signal:

• Technical factors:

  • Insufficient phosphatase inhibition during sample preparation

  • Inadequate antigen retrieval for IHC/IF applications

  • Signal loss during long storage of prepared samples

  • Antibody deterioration (freeze-thaw cycles, improper storage)

• Biological factors:

  • Rapid dephosphorylation kinetics of S36 (requiring precise timing of sample collection)

  • Cell type-specific phosphatase activity

  • Low expression of p66Shc isoform in certain cell types

  • Mutual antagonism between different phosphorylation sites

• Experimental design issues:

  • Suboptimal stimulation conditions (duration, concentration)

  • Selection of inappropriate time points for harvesting

  • Culture conditions affecting stress response pathways

For optimization, researchers should first establish a positive control (e.g., H₂O₂ treatment of HeLa cells) and systematically troubleshoot from sample preparation through detection .

How can phospho-SHC1 (S36) antibodies be utilized in multiplexed phosphoprotein analysis?

Advanced multiplexed approaches for phospho-SHC1 (S36) analysis include:

• Multiplex phosphoprotein bead arrays:

  • Allows simultaneous detection of phospho-SHC1 (S36) alongside other phosphoproteins

  • Enables correlation of p66Shc activation with other signaling nodes

  • Has been validated in cellular kinase activity assays

• Mass cytometry (CyTOF):

  • Can be used with metal-conjugated phospho-SHC1 (S36) antibodies

  • Permits single-cell resolution of phosphorylation states

  • Enables correlation with dozens of other cellular markers

• Multiplex immunofluorescence:

  • Tyramide signal amplification allows detection of multiple phospho-epitopes

  • Can localize phospho-SHC1 (S36) relative to subcellular compartments and other proteins

  • Useful for spatial relationships between phospho-SHC1 and mitochondria

• Phosphoproteomic integration:

  • Combining antibody-based methods with MS-based phosphoproteomics

  • Use phospho-SHC1 (S36) antibodies for enrichment prior to MS analysis

  • Creates comprehensive phosphorylation maps of SHC1 and interacting partners

How can researchers determine the functional consequences of SHC1 S36 phosphorylation in different cellular contexts?

To establish functional outcomes of S36 phosphorylation:

• Genetic approaches:

  • Express phosphomimetic (S36E) or phospho-deficient (S36A) mutants

  • Use CRISPR/Cas9 to create endogenous S36A mutations

  • Rescue experiments in SHC1-knockout backgrounds

• Pharmacological interventions:

  • JNK inhibitors to prevent S36 phosphorylation

  • Antioxidants to assess ROS-dependent effects downstream of S36 phosphorylation

  • Mitochondrial targeting compounds to isolate organelle-specific effects

• Functional readouts:

  • Measure mitochondrial ROS production using specific probes

  • Assess mitochondrial translocation of p66Shc

  • Quantify cellular ATP content and superoxide production

  • Measure apoptosis and cell death rates

• Interactome analysis:

  • Immunoprecipitation of wild-type versus S36 mutant SHC1

  • Affinity purification-mass spectrometry to identify phosphorylation-dependent binding partners

  • Proximity labeling to capture transient interactions

What is the relationship between SHC1 S36 phosphorylation and phosphorylation at other sites within the protein?

The interplay between different SHC1 phosphorylation sites involves complex regulatory mechanisms:

• Site relationships:

  • S36 phosphorylation occurs primarily on p66Shc isoform

  • Y239/240 and Y313 phosphorylation occurs on all three isoforms (p66, p52, p46)

  • Evidence suggests that S36 phosphorylation can influence accessibility of tyrosine sites

• Hierarchical phosphorylation:

  • S36 phosphorylation may precede and enable other modifications

  • The ratio of phosphorylated S36 to total p66Shc decreases in certain stress conditions, suggesting complex regulation

• Distinct effector pathways:

  • Y239/240 phosphorylation primarily recruits Grb2, ARHGEF5, and GAREM proteins

  • Y313 phosphorylation recruits lipid signaling proteins Plcg1 and Plcg2

  • S36 phosphorylation primarily affects mitochondrial localization and function

  • Different phosphorylation patterns create distinct protein complexes with unique signaling outcomes

• Analytical approaches:

  • Use multiply phosphorylated synthetic protein fragments to study combinatorial effects

  • Apply phospho-specific antibodies in sequential immunoprecipitation experiments

  • Employ mass spectrometry to quantify all phosphorylation sites simultaneously

How are phospho-SHC1 (S36) antibodies being applied in clinical and translational research?

Emerging translational applications include:

• Diagnostic biomarker development:

  • Phospho-SHC1 (S36) levels as indicators of oxidative stress in clinical samples

  • Potential prognostic marker in ischemia/reperfusion injuries

  • Correlation with treatment responses in cancer therapies targeting stress pathways

• Drug discovery applications:

  • High-throughput screening for compounds that modulate S36 phosphorylation

  • Target engagement biomarker for JNK inhibitors in development

  • Tool for assessing efficacy of antioxidant therapies

• Personalized medicine approaches:

  • Assessment of patient-specific responses to oxidative stress

  • Stratification of patients for therapies targeting stress-response pathways

  • Monitoring treatment efficacy in real-time

What are the technical limitations of current phospho-SHC1 (S36) antibodies and how might they be overcome?

Current limitations and emerging solutions include:

• Sensitivity limitations:

  • Current antibodies may miss low-level phosphorylation

  • Solution: Development of more sensitive detection methods (SiMoA, ELISA-PCR)

• Specificity challenges:

  • Cross-reactivity with similar phospho-epitopes

  • Solution: Generation of more specific monoclonal antibodies using strategic immunization approaches

• Temporal resolution:

  • Inability to capture rapid phosphorylation dynamics

  • Solution: Development of phospho-biosensors for live-cell imaging of S36 phosphorylation

• Spatial resolution:

  • Limited ability to detect subcellular pools of phosphorylated protein

  • Solution: Proximity ligation assays and super-resolution microscopy techniques

• Quantification challenges:

  • Difficulties in absolute quantification of phosphorylation stoichiometry

  • Solution: Integration with mass spectrometry-based absolute quantification approaches